Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Hector E Sanchez-Ibarra"'
Autor:
Hector E. Sanchez-Ibarra, Luisa M. Reyes-Cortes, Xian-Li Jiang, Claudia M. Luna-Aguirre, Dionicio Aguirre-Trevino, Ivan A. Morales-Alvarado, Rafael B. Leon-Cachon, Fernando Lavalle-Gonzalez, Faruck Morcos, Hugo A. Barrera-Saldaña
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
The treatment of Type 2 Diabetes Mellitus (T2DM) consists primarily of oral antidiabetic drugs (OADs) that stimulate insulin secretion, such as sulfonylureas (SUs) and reduce hepatic glucose production (e.g., biguanides), among others. The marked int
Externí odkaz:
https://doaj.org/article/e8dc387a52c344119133d7c99c2eeebd
Autor:
Mauricio Rodríguez-Dorantes, Sergio Villicaña, Sergio Alberto Cortés-Ramírez, Hugo A. Barrera-Saldaña, Hector E. Sanchez-Ibarra, Fernando J. Lavalle-González, Vanessa Gonzalez-Covarrubias, Karla Lozano-Gonzalez, Xavier Soberón, Tomas Texis
Publikováno v:
Pharmacology. 106:588-596
Introduction: Genetic variants could aid in predicting antidiabetic drug response by associating them with markers of glucose control, such as glycated hemoglobin (HbA1c). However, pharmacogenetic implementation for antidiabetics is still under devel
Autor:
Yan Shixian, Paul Schöpe, Joe Lewis, Kerstin Putzker, Ulrike Uhrig, Edgar Specker, Jens von Kries, Hector E. Sanchez-Ibarra, Anke Unger, Mia Zischinsky, Bert Klebl, Peter Lindemann, Wolfgang Walther, Marc Nazaré, Dennis Kobelt, Ulrike Stein
Publikováno v:
Cancer Research. 83:2471-2471
Cancer metastasis is the most lethal attribute of cancer, frequently caused by insufficient therapies and limited therapy options. Novel compounds able to interfere with metastasis formation are therefore of tremendous interest. Colorectal Cancer (CR
Autor:
Paul Curtis Schöpe, Shixian Yan, Dennis Kobelt, Joe Lewis, Kerstin Putzker, Ulrike Uhrig, Edgar Specker, Jens Peter von Kries, Mathias Dahlmann, Hector E Sanchez-Ibarra, Anke Unger, Mia-Lisa Zischinsky, Bert Klebl, Peter Lindemann, Wolfgang Walther, Marc Nazaré, Ulrike Stein
Publikováno v:
Cancer Research. 83:A039-A039
The leading cause of cancer related deaths is the formation of metastasis, frequently caused by insufficient therapies and limited therapy options. Novel compounds able to interfere with metastasis formation are therefore of tremendous interest. Colo
Autor:
Claudia M. Luna-Aguirre, Luisa M. Reyes-Cortes, Esteban López-Tavera, Hugo A. Barrera-Saldaña, Hector E. Sanchez-Ibarra
Publikováno v:
Revista de investigaci�n Cl�nica. 72
espanolAntecedentes: la presencia de mutaciones clinicamente relevantes en losgenes KRAS y NRAS determina la respuesta de la terapia con anticuerpos anti-receptor del factor de crecimiento epidermico para el cancer colorrectal metastasico (mCRC). Las
Autor:
Hector E. Sanchez-Ibarra, Hugo A. Barrera-Saldaña, Yenho Chen, Faruck Morcos, Adriana Carolina Cavazos-González, Xian-Li Jiang, Elena Yareli Gallegos-Gonzalez
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 7, p e0235490 (2020)
PLoS ONE, Vol 15, Iss 7, p e0235490 (2020)
Mutations in KRAS, NRAS, and BRAF (RAS/BRAF) genes are the main predictive biomarkers for the response to anti-EGFR monoclonal antibodies (MAbs) targeted therapy in metastatic colorectal cancer (mCRC). This retrospective study aimed to report the mut